TY - JOUR
T1 - Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation
AU - The IeDEA, COHERE, PHACS and IMPAACT 219C Collaborations Writing Group
AU - Panayidou, Klea
AU - Davies, Mary Ann
AU - Anderegg, Nanina
AU - Egger, Matthias
AU - Fatti, Geoffrey
AU - Vinikoor, Michael
AU - Sawry, Shobna
AU - Ehmer, Jochen
AU - Eley, Brian
AU - Phiri, Sam
AU - Technau, Karl G.Ü.Nter
AU - Chimbetete, Cleophas
AU - Rabie, Helena
AU - Boulle, Andrew
AU - Tanser, Frank
AU - Wood, Robin
AU - Wools-Kaloustian, Kara
AU - Vreeman, Rachel
AU - Oyaro, Patrick
AU - Ayaya, Samuel
AU - Nakigozi, Gertrude
AU - Musick, Beverley
AU - Yiannoutsos, Constantin
AU - Amorissani-Folquet, Madeleine
AU - Takassi, Elom
AU - Sylla, Mariam
AU - Renner, Lorna
AU - Malateste, Karen
AU - Desmonde, Sophie
AU - Leroy, Valériane
AU - Kurniati, Nia
AU - Hansudewechakul, Rawiwan
AU - Nguyen, Lam Van
AU - Ly, Penh Sun
AU - Truong, Khanh Huu
AU - Kariminia, Azar
AU - Sohn, Annette H.
AU - Edmonds, Andrew
AU - Yumo, Habakkuk Azinyui
AU - Dusingize, Jean Claude
AU - Yotebieng, Marcel
AU - Judd, Ali
AU - Rojo, Pablo
AU - Smit, Colette
AU - Grabar, Sophie
AU - Warszwarski, Josiane
AU - Chene, Genevieve
AU - Raban, Dorthe
AU - Oleske, James
AU - Hoover, Don
N1 - Funding Information:
The International Epidemiology Databases to Evaluate AIDS (IeDEA) collaboration is supported by the core regional IeDEA grants through the National Institute of Allergy And Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA): U01AI069907 (Asia-Pacific), U01AI069923 (CCASAnet), U01AI096299 (Central Africa), U01AI069911 (East Africa), U01AI069924 (Southern Africa), U01AI069919 (West Africa). The Kirby Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, University of New South Wales. The NICHD Site Development Initiative (NISDI) was funded by the NIH and NICHD (contracts N01-HD-3-3345 and N01-HD-8-0001). The COHERE study group has received unrestricted funding from: Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), France and the Augustinus Foundation, Denmark. The Netherlands ATHENA database is maintained by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment, The Netherlands. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement no. 260694. A list of the funders of the participating cohorts can be found at www.COHERE.org. The Pediatric HIV/AIDS Cohort Study (PHACS) was supported by NICHD with co-funding from the National Institute Of Dental & Craniofacial Research (NIDCR), NIAID, the National Institute Of Neurological Disorders And Stroke (NINDS), the National Institute On Deafness And Other Communication Disorders (NIDCD), Office of AIDS Research (OAR), NIMH, the National Institute On Drug Abuse (NIDA) and the National Institute On Alcohol Abuse And Alcoholism (NIAAA), through cooperative agreements with the Harvard T.H. Chan School of Public Health (HD052102) and the Tulane University School of Medicine (HD052104). Over-all support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by NIAID [U01AI068632] and the NICHD International and Domestic Pediatric and Maternal HIV Clinical Trials Network supported by NICHD [contract N01-3-3345 and HHSN267200800001C]. This work was supported by the Statistical and Data Analysis Center at Harvard School of Public Health, under NIAID cooperative agreement U01AI41110 with the Pediatric AIDS Clinical Trials Group (PACTG) and U01AI068616 with the IMPAACT Group. This study was also supported by special project funding (Grant No. 174281) from the Swiss National Science Foundation.
Funding Information:
The International Epidemiology Databases to Evaluate AIDS (IeDEA) collaboration is supported by the core regional IeDEA grants through the National Institute of Allergy And Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute of Mental Health (NIMH) and the National Institute on Drug Abuse (NIDA): U01AI069907 (Asia-Pacific), U01AI069923 (CCASAnet), U01AI096299 (Central Africa), U01AI069911 (East Africa), U01AI069924 (Southern Africa), U01AI069919 (West Africa). The Kirby Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, University of New South Wales. The NICHD Site Development Initiative (NISDI) was funded by the NIH and NICHD (contracts N01-HD-3-3345 and N01-HD-8-0001).
Publisher Copyright:
© 2018 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease. Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines. Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries). Conclusions: By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to <20% in high-income countries.
AB - Introduction: The CD4 cell count and percent at initiation of combination antiretroviral therapy (cART) are measures of advanced HIV disease and thus are important indicators of programme performance for children living with HIV. In particular, World Health Organization (WHO) 2017 guidelines on advanced HIV disease noted that >80% of children aged <5 years started cART with WHO Stage 3 or 4 disease or severe immune suppression. We compared temporal trends in CD4 measures at cART start in children from low-, middle- and high-income countries, and examined the effect of WHO treatment initiation guidelines on reducing the proportion of children initiating cART with advanced disease. Methods: We included children aged <16 years from the International Epidemiology Databases to Evaluate acquired immunodeficiency syndrome (AIDS) (IeDEA) Collaboration (Caribbean, Central and South America, Asia-Pacific, and West, Central, East and Southern Africa), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), the North American Pediatric HIV/AIDS Cohort Study (PHACS) and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 219C study. Severe immunodeficiency was defined using WHO guidelines. We used generalized weighted additive mixed effect models to analyse temporal trends in CD4 measurements and piecewise regression to examine the impact of 2006 and 2010 WHO cART initiation guidelines. Results: We included 52,153 children from fourteen low-, eight lower middle-, five upper middle- and five high-income countries. From 2004 to 2013, the estimated percentage of children starting cART with severe immunodeficiency declined from 70% to 42% (low-income), 67% to 64% (lower middle-income) and 61% to 43% (upper middle-income countries). In high-income countries, severe immunodeficiency at cART initiation declined from 45% (1996) to 14% (2012). There were annual decreases in the percentage of children with severe immunodeficiency at cART initiation after the WHO guidelines revisions in 2006 (low-, lower middle- and upper middle-income countries) and 2010 (all countries). Conclusions: By 2013, less than half of children initiating cART had severe immunodeficiency worldwide. WHO treatment initiation guidelines have contributed to reducing the proportion of children and adolescents starting cART with advanced disease. However, considerable global inequity remains, in 2013, >40% of children in low- and middle-income countries started cART with severe immunodeficiency compared to <20% in high-income countries.
KW - Asia
KW - CD4 cell count
KW - Caribbean
KW - Central and South America
KW - Europe
KW - North America
KW - WHO guidelines
KW - advanced HIV disease
KW - antiretroviral therapy
KW - sub-Saharan Africa
UR - http://www.scopus.com/inward/record.url?scp=85057606927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057606927&partnerID=8YFLogxK
U2 - 10.1002/jia2.25200
DO - 10.1002/jia2.25200
M3 - Article
C2 - 30614622
AN - SCOPUS:85057606927
SN - 1758-2652
VL - 21
JO - Journal of the International AIDS Society
JF - Journal of the International AIDS Society
IS - 11
M1 - e25200
ER -